NASDAQ:MISTMilestone Pharmaceuticals Stock Price, Forecast & News

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MIST stock has decreased by 82.4% and is now trading at $3.51. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Milestone Pharmaceuticals.

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Milestone Pharmaceuticals.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.07. View Milestone Pharmaceuticals' earnings history.

6 Wall Street analysts have issued 1-year target prices for Milestone Pharmaceuticals' shares. Their forecasts range from $3.00 to $32.00. On average, they expect Milestone Pharmaceuticals' share price to reach $21.42 in the next twelve months. This suggests a possible upside of 510.2% from the stock's current price. View analysts' price targets for Milestone Pharmaceuticals.

News articles about MIST stock have trended very negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Milestone Pharmaceuticals earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMilestone Pharmaceuticals.

Milestone Pharmaceuticals saw a decrease in short interest in May. As of May 15th, there was short interest totaling 398,100 shares, a decrease of 8.8% from the April 30th total of 436,500 shares. Based on an average daily trading volume, of 1,520,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 3.2% of the shares of the company are short sold. View Milestone Pharmaceuticals' Current Options Chain.

Some companies that are related to Milestone Pharmaceuticals include Kamada (KMDA), Selecta Biosciences (SELB), Geron (GERN), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Urovant Sciences (UROV), OrganiGram (OGI), 89bio (ETNB), Osmotica Pharmaceuticals (OSMT), Lannett (LCI), MannKind (MNKD), Verastem (VSTM), Verrica Pharmaceuticals (VRCA), Bicycle Therapeutics (BCYC) and Avadel Pharmaceuticals (AVDL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA), Opko Health (OPK), AbbVie (ABBV), Walt Disney (DIS), Gilead Sciences (GILD), SCYNEXIS (SCYX), Amplify Energy (AMPY), Amplify Energy (AMPY), Energy Transfer LP Unit (ET) and Menlo Therapeutics (MNLO).

(MIST) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

Milestone Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Tekla Capital Management LLC (0.87%), Ghost Tree Capital LLC (0.85%), Sphera Funds Management LTD. (0.28%) and UBS Group AG (0.05%). Company insiders that own Milestone Pharmaceuticals stock include Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP. View institutional ownership trends for Milestone Pharmaceuticals.

MIST stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, and Ghost Tree Capital LLC. View insider buying and selling activity for Milestone Pharmaceuticals.

MIST stock was bought by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., and UBS Group AG. Company insiders that have bought Milestone Pharmaceuticals stock in the last two years include Holdings A/S Novo, Rtw Investments, Lp, and Stonepine Capital, LP. View insider buying and selling activity for Milestone Pharmaceuticals.

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MIST stock can currently be purchased for approximately $3.51.

Milestone Pharmaceuticals has a market capitalization of $86.38 million. The company earns $-55,230,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis. Milestone Pharmaceuticals employs 20 workers across the globe.

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]